TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH"), announced today that it will host a conference call and webcast on Monday, November 5, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the three and nine months ended September 30, 2018.
Conference Call & Webcast: |
|
Monday, November 5 @ 8:30am Eastern Time |
|
Within the US: |
800-239-9838 |
Outside the US: |
323-794-2551 |
From Israel: |
1809 212 883 |
Conference ID: |
9320949 |
Webcast: |
|
Replays, Available through November 19: |
|
Domestic: |
844-512-2921 |
International: |
412-317-6671 |
Replay PIN: |
9320949 |
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.
SOURCE Galmed Pharmaceuticals Ltd.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article